NCT04810611View on ClinicalTrials.gov

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

PHASE1TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

April 19, 2024

Study Completion Date

April 19, 2024

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

MBG453

Anti-TIM3 monoclonal antibody

DRUG

NIS793

Anti-TGF-β monoclonal antibody

DRUG

canakinumab

Anti-IL-1β monoclonal antibody

Trial Locations (13)

3181

Novartis Investigative Site, Prahran

20162

Novartis Investigative Site, Milan

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

37007

Novartis Investigative Site, Salamanca

43210

The Ohio State University Wexner Medical Center ., Columbus

77030

MD Anderson Cancer Center/University of Texas MD Anderson, Houston

91010

City Of Hope National Med Center Oncology, Duarte

119228

Novartis Investigative Site, Singapore

169608

Novartis Investigative Site, Singapore

6423906

Novartis Investigative Site, Tel Aviv

02114

Massachusetts General Hospital ., Boston

03080

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY